Human RctHighOff Label
Does rapamycin slow aging in humans?
Rapamycin is one of the most discussed geroscience drugs, but human longevity evidence remains incomplete.
Jun 27, 20265 min readrapamycin / sirolimus
Longevity Drugs
Rapamycin, metformin, acarbose, GLP-1s, SGLT2 inhibitors and other drugs discussed as geroprotectors.
Who this is for
People tracking prescription-drug longevity debates who need a cleaner read on human outcomes, off-label use and clinical uncertainty.
Key questions answered
Is the evidence about aging itself or a disease proxy?
Is use approved, off-label or trial-only?
What outcomes matter beyond biomarkers?
What monitoring questions belong with a clinician?
Featured articles
Human RctHighOff Label
What did the PEARL rapamycin trial actually show?
PEARL is important because it asks human questions, but readers should distinguish trial signals from sweeping longevity claims.
Jun 27, 20265 min readPEARL / rapamycin
Clinical Trial RegisteredModerateFda Approved For Other Use
Metformin for longevity: what TAME is trying to answer.
TAME is designed around whether one approved diabetes drug can affect multiple aging-related outcomes, but it is not a completed answer.
Jun 27, 20265 min readmetformin / TAME
Latest signals
ClinicalTrials.gov
Jun 27, 2026
Clinical Trial RegisteredHighOff Label
Rapamycin longevity claims should be mapped to registered human endpoints
Registry searches help distinguish actual human study questions from podcast-level certainty.
A registered trial is stronger than anecdote, but interpretation depends on design, outcomes and reporting.
Glossary
- Geroprotector
- A proposed intervention intended to modify biological aging processes, not merely treat one disease endpoint.
- Off-label
- Use of an approved drug outside its FDA-approved indication, population or condition.
FAQs
Do approved drugs become approved longevity drugs automatically?
No. Approval for one medical use does not establish approval for longevity or aging claims.